Climb Bio (CLYM) Long-Term Investments (2021 - 2026)
Climb Bio's (CLYM) quarterly Long-Term Investments came in at $36.7 million in Q1 2026, down 63.18% YoY from $99.8 million in Q1 2025, and down 38.33% on a QoQ basis from $59.6 million in Q4 2025.
Climb Bio (CLYM) Long-Term Investments (2021 - 2026) Analysis & Trends
Climb Bio (CLYM) has 5 years of Long-Term Investments data on file, last reported at $36.7 million in Q1 2026.
- Quarterly Long-Term Investments fell 63.18% year-over-year to $36.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $36.7 million (down 63.18% YoY) and the FY2025 annual result came in at $59.6 million, down 3.31% from the prior year.
- Long-Term Investments retreated to $36.7 million in Q1 2026, from $59.6 million in the prior quarter.
- In the past five years, Long-Term Investments ranged from a high of $102.7 million in Q2 2025 to a low of $7.0 million in Q3 2022.
- A 4-year average of $51.8 million and a median of $48.2 million in 2025 frame the typical range for Long-Term Investments.
- Annual changes were most pronounced in 2022 — Long-Term Investments plunged 70.53% — and 2025, when it surged 261.86%.
- Tracing CLYM's Long-Term Investments over 4 years: stood at $7.0 million in 2022, then soared by 785.07% to $61.6 million in 2024, then retreated by 3.31% to $59.6 million in 2025, then plunged by 38.33% to $36.7 million in 2026.
- The last three Long-Term Investments figures came in at $36.7 million (Q1 2026), $59.6 million (Q4 2025), and $88.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 372.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.17 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Climb Bio | 1.24 Bn | 1.24 Bn | - | 56.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 56.10 Mn |
| Mar 31, 2026 | 36.74 Mn |
| Dec 31, 2025 | 59.57 Mn |
| Sep 30, 2025 | 88.93 Mn |
| Jun 30, 2025 | 102.70 Mn |
| Mar 31, 2025 | 99.78 Mn |
| Dec 31, 2024 | 61.61 Mn |
| Sep 30, 2024 | 24.58 Mn |
| Sep 30, 2022 | 6.96 Mn |
| Jun 30, 2022 | 11.70 Mn |
| Mar 31, 2022 | 25.91 Mn |
| Dec 31, 2021 | 24.92 Mn |
| Sep 30, 2021 | 23.62 Mn |